MP01-01 EXIME® URETHRAL STENT IMPLANTATION (EUSI) AS INITIAL TREATMENT FOR PATIENTS PRESENTING WITH ACUTE URINARY RETENTION (AUR) FOR THE FIRST TIME AS A RESULT OF BPH

Abstract

You have accessJournal of UrologyCME1 May 2022MP01-01 EXIME® URETHRAL STENT IMPLANTATION (EUSI) AS INITIAL TREATMENT FOR PATIENTS PRESENTING WITH ACUTE URINARY RETENTION (AUR) FOR THE FIRST TIME AS A RESULT OF BPH Nordine Amara, Tarek Al Youssef, Jordan Massa, Elias Elkhouri, and Belur Patel Nordine AmaraNordine Amara More articles by this author , Tarek Al YoussefTarek Al Youssef More articles by this author , Jordan MassaJordan Massa More articles by this author , Elias ElkhouriElias Elkhouri More articles by this author , and Belur PatelBelur Patel More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002513.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Acute urinary retention (AUR) is a painful and distressing condition which is associated with significant morbidity requiring hospitalization, catheterization and often surgery. AUR often develops from benign prostatic hyperplasia (BPH) and its incidence increases with age. Management will often necessitates the insertion of a urinary catheter. We studied the efficacy of Exime® urethral stent implantation (EUSI) as initial treatment for patients presenting with acute urinary retention (AUR) for the first time as a result of BPH. METHODS: From January 2019 to January 2022 61 BPH patients underwent EUSI. The patients were aged 52–91 years old (mean 67.3 years), with a prostate volume of 30–120 ml (mean 67 ml) and IPSS score of 24±5.7. The same technique for insertion of EUSI under local anesthesia was used for each patient. RESULTS: Of the 61 patients 55 (90%) achieved spontaneous urination immediately after procedure; 3 patients (4.9%) developed urinary infection symptoms; 3 patients (4.9%) experienced bladder clot retention. No urethral injury and no false route were noted. CONCLUSIONS: EUSI, with its advantages of simple operation, high safety, definite effectiveness, is a new effective option for the treatment of AUR due to BPH. As more minimally invasive, office-based technologies emerge, physician and patients will have the ability to choose a treatment that is more catered to patient expectations. Further studies are needed to better define its place in this setting. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e1 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nordine Amara More articles by this author Tarek Al Youssef More articles by this author Jordan Massa More articles by this author Elias Elkhouri More articles by this author Belur Patel More articles by this author Expand All Advertisement PDF DownloadLoading ...